trial

Relative Bioavailability of LY03010 Compared to Listed Drug

NCTId NCT04922593
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 281 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2022-03-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
281 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2021-01-13
Primary completion
2022-03-15
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Luye Pharma Group Ltd.Lead Sponsor

Investigators

1
Rui Li, MDStudy Chair

Sites

9 total
Garden Grove, United StatesLemon Grove, United StatesTorrance, United StatesMiami Lakes, United StatesChicago, United StatesBerlin, United StatesMarlton, United StatesDeSoto, United StatesRichardson, United States

Facts & assertions

4 sourced
Enrollment
281
Phase
PHASE1
Primary Completion Date
2022-03-15
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Luye Pharma Group Ltd.
company
indication
Central Nervous System Depressants
indication
Neurotransmitter Agents
indication
Psychotic Disorders
indication
investigator
Rui Li, MD
person